Vincristine neurotoxicity in Charcot-Marie-Tooth syndrome.
The case of a patient with Charcot-Marie-Tooth syndrome and diffuse large-cell lymphoma, in whom a severe generalized weakness developed after the intravenous administration of vincristine (2 mg) during combination chemotherapy, is reported. Spontaneous resolution of the severe weakness occurred when teniposide was substituted for vincristine in the chemotherapy regimen.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002607:Charcot-Marie-Tooth Disease / Q000150:complications* / Q000188:drug therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008223:Lymphoma / Q000150:complications / Q000188:drug therapy; D008875:Middle Aged; D009133:Muscular Atrophy / Q000150:complications*; D009468:Neuromuscular Diseases / Q000139:chemically induced* / Q000473:pathology; D011239:Prednisolone / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects*
D014750:Vincristine; D003520:Cyclophosphamide; D011239:Prednisolone